Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016

Antibiotics play an important role for the treatment and prevention of invasive Haemophilus influenzae disease. Antimicrobial resistance survey of invasive H. influenzae isolates collected in 2016 showed that the US H. influenzae population remained susceptible to clinically relevant antibiotics, except for ampicillin. ABSTRACT Antibiotics are important for the treatment and prevention of invasive Haemophilus influenzae disease. Reduced susceptibility to clinically relevant drugs, except ampicillin, has been uncommon in the United States. Susceptibility of 700 invasive H. influenzae isolates, collected through population-based surveillance during 2016, was assessed for 15 antibiotics using broth microdilution, according to the CLSI guidelines; a subset of 104 isolates were also assessed for rifampin susceptibility using Etest. Genomes were sequenced to identify genes and mutations known to be associated with reduced susceptibility to clinically relevant drugs. A total of 508 (72.6%) had reduced susceptibility to at least one antibiotic and more than half of the isolates exhibited reduced susceptibility to only one (33.6%) or two (21.6%) antibiotic classes. All tested isolates were susceptible to rifampin, a chemoprophylaxis agent, and <1% (n = 3) of isolates had reduced susceptibility to third generation cephalosporins, which are recommended for invasive disease treatment. In contrast, ampicillin resistance was more common (28.1%) and predominantly associated with the detection of a β-lactamase gene; 26.2% of isolates in the collection contained either a TEM-1 or ROB-1 β-lactamase gene, including 88.8% of ampicillin-resistant isolates. β-lactamase negative ampicillin-resistant (BLNAR) isolates were less common and associated with ftsI mutations; resistance to amoxicillin-clavulanate was detected in <2% (n = 13) of isolates. The proportion of reduced susceptibility observed was higher among nontypeable H. influenzae and serotype e than other serotypes. US invasive H. influenzae isolates remain predominantly susceptible to clinically relevant antibiotics except ampicillin, and BLNAR isolates remain uncommon. IMPORTANCE Antibiotics play an important role for the treatment and prevention of invasive Haemophilus influenzae disease. Antimicrobial resistance survey of invasive H. influenzae isolates collected in 2016 showed that the US H. influenzae population remained susceptible to clinically relevant antibiotics, except for ampicillin. Detection of approximately a quarter ampicillin-resistant and β-lactamase containing strains demonstrates that resistance mechanisms can be acquired and sustained within the H. influenzae population, highlighting the continued importance of antimicrobial resistance surveillance for H. influenzae to monitor susceptibility trends and mechanisms of resistance.

[1]  H. Claus,et al.  Molecular epidemiology of imipenem resistance in invasive Haemophilus influenzae infections in Germany in 2016. , 2020, The Journal of antimicrobial chemotherapy.

[2]  Adam C. Retchless,et al.  Genomic characterization of Haemophilus influenzae: a focus on the capsule locus , 2019, BMC Genomics.

[3]  Keith A Jolley,et al.  Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications , 2018, Wellcome open research.

[4]  W. Schaffner,et al.  Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease—United States, 2009–2015 , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  P. François,et al.  Molecular characterization of fluoroquinolones, macrolides, and imipenem resistance in Haemophilus influenzae: analysis of the mutations in QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  P. François,et al.  Imipenem heteroresistance in nontypeable Haemophilus influenzae is linked to a combination of altered PBP3, slow drug influx and direct efflux regulation. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  W. Schaffner,et al.  Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease—United States, 2009–2014 , 2016 .

[8]  C. Sacchi,et al.  Development of Real-Time PCR Methods for the Detection of Bacterial Meningitis Pathogens without DNA Extraction , 2016, PloS one.

[9]  W. Schaffner,et al.  Twenty Years of Active Bacterial Core Surveillance , 2015, Emerging infectious diseases.

[10]  A. Sundsfjord,et al.  Emergence of clonally related multidrug resistant Haemophilus influenzae with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  Ronald N. Jones,et al.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). , 2014, Diagnostic microbiology and infectious disease.

[12]  Raydel D. Mair,et al.  Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Raydel D. Mair,et al.  Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae. , 2011, International journal of medical microbiology : IJMM.

[14]  Bartek Wilczynski,et al.  Biopython: freely available Python tools for computational molecular biology and bioinformatics , 2009, Bioinform..

[15]  N. Yamanaka,et al.  Genetic Characteristics and Clonal Dissemination of β-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Strains Isolated from the Upper Respiratory Tract of Patients in Japan , 2007, Antimicrobial Agents and Chemotherapy.

[16]  M. Cerquetti,et al.  First Characterization of Heterogeneous Resistance to Imipenem in Invasive Nontypeable Haemophilus influenzae Isolates , 2007, Antimicrobial Agents and Chemotherapy.

[17]  M. Jacobs,et al.  Antimicrobial Resistance in Haemophilus influenzae , 2007, Clinical Microbiology Reviews.

[18]  A. MacGowan,et al.  Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. , 2003, The Journal of antimicrobial chemotherapy.

[19]  T. Popović,et al.  Identification of Haemophilus influenzae Serotypes by Standard Slide Agglutination Serotyping and PCR-Based Capsule Typing , 2003, Journal of Clinical Microbiology.

[20]  C. Pasquier,et al.  Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae , 2002, Antimicrobial Agents and Chemotherapy.

[21]  A. Evangelista,et al.  Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Karlowsky,et al.  Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis , 2002, Antimicrobial Agents and Chemotherapy.

[23]  K. Yamamoto,et al.  Association of Amino Acid Substitutions in Penicillin-Binding Protein 3 with β-Lactam Resistance in β-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae , 2001, Antimicrobial Agents and Chemotherapy.

[24]  G. Doern,et al.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Kahn,et al.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. , 1997, Diagnostic microbiology and infectious disease.

[26]  M. Jacobs,et al.  Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid. , 1997, Diagnostic microbiology and infectious disease.

[27]  G. Doern,et al.  Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study , 1997, Antimicrobial agents and chemotherapy.

[28]  G. Doern.  Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. , 1995, The American journal of medicine.

[29]  C Thornsberry,et al.  Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria , 1991, Journal of clinical microbiology.

[30]  J. Jorgensen,et al.  Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E-test , 1991, Journal of clinical microbiology.

[31]  R. Yolken,et al.  AMPICILLIN TREATMENT FAILURE OF APPARENTLY β-LACTAMASE-NEGATIVE HAEMOPHILUS INFLUENZAE TYPE b MENINGITIS DUE TO NOVEL β-LACTAMASE , 1981, The Lancet.

[32]  E. Bottone,et al.  Spheroplasts of Haemophilus influenzae Induced by Cell Wall-Active Antibiotics and Their Effect upon the Interpretation of Susceptibility Tests , 1976, Antimicrobial Agents and Chemotherapy.

[33]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[34]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.

[35]  R. Yolken,et al.  Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase. , 1981, Lancet.

[36]  A. Medeiros,et al.  Ampicillin-resistant Haemophilus influenzae type B possessing a TEM-type beta-lactamase but little permeability barrier to ampicillin. , 1975, Lancet.